Menopausal Hormone Therapy: Evidence Overview

Menopausal hormone therapy (MHT, sometimes called HRT) has been studied for decades, and the way experts interpret that evidence has evolved considerably. This page summarizes, in plain language, what major guidelines and the broad body of research generally conclude.

What question is menopausal hormone therapy meant to answer?

Menopause is the natural point when menstrual periods stop and the ovaries produce much less estrogen and progesterone. The transition leading up to it, and the years that follow, can bring symptoms that range from barely noticeable to genuinely disruptive — hot flashes, night sweats, disturbed sleep, mood changes, and vaginal and urinary symptoms among them. Menopausal hormone therapy replaces some of the hormones the body no longer makes in the same amounts, with the goal of relieving those symptoms and, in some situations, protecting bone.

The questions the evidence tries to answer are who is likely to benefit, which symptoms respond best, what the risks are, and how those risks change with a person's age, health, and the type of therapy used. Much of the public confusion around MHT comes from treating it as a single yes-or-no decision, when in reality it is a family of treatments with different formulations, doses, and delivery routes.

What menopausal hormone therapy is for

Major menopause and gynecology guidelines broadly agree that the clearest, best-supported use of MHT is to relieve bothersome menopausal symptoms — especially hot flashes and night sweats — and genitourinary symptoms such as vaginal dryness. For symptom relief, the body of evidence is consistent and strong. MHT is also recognized as helpful for preserving bone density.

Therapy generally combines estrogen with a progestogen for people who have a uterus, because estrogen alone can overstimulate the uterine lining; the progestogen protects that lining. Estrogen alone is typically used after hysterectomy. Low-dose vaginal estrogen is treated separately in the guidelines as a localized option for genitourinary symptoms, because it acts mainly where it is applied and is generally considered to carry a different risk profile from therapy that circulates throughout the body.

The "timing" theme in the evidence

One of the most important shifts in interpretation is the idea of a timing or "window" effect. The broad body of evidence suggests the balance of benefits and risks is generally more favorable for healthy people who begin therapy near the onset of menopause and who are younger, compared with starting many years later. Guidelines now emphasize individualizing decisions by age, time since menopause, symptom burden, and personal risk factors rather than applying one rule to everyone.

This shift is a useful example of how medical understanding matures. Earlier interpretations of large studies tended to average across very different groups of people; later analysis paid closer attention to age and how long it had been since menopause, and a more nuanced picture emerged. The underlying data did not change so much as the way it was understood.

What the evidence broadly shows about risks

Commonly discussed risks include blood clots, stroke, and — depending on the type, dose, route, and duration — breast cancer. The evidence indicates these risks vary by formulation (for example, the route of estrogen and the choice of progestogen) and by the individual's baseline health. Guidelines stress that absolute risks for an otherwise healthy person near menopause are generally modest, while emphasizing that they are real and should be discussed rather than dismissed.

Just as important is what the evidence does not support: MHT is not generally recommended purely to prevent chronic diseases such as heart disease or dementia, and using it for those goals alone is not backed by strong trial evidence. The strongest case for therapy remains symptom relief in people who are bothered by symptoms.

Where the evidence is still developing

Active research questions include how different formulations and delivery routes compare over the long term, the optimal duration of therapy, effects on heart and brain health when started at different ages, and the best options for people who cannot or prefer not to use hormones. Comparisons between specific products are an ongoing area, and individual risk profiles can change the overall picture substantially. Non-hormonal approaches for symptom relief are also an area of continued study and interest.

What guidelines say and what it means for patients

The common thread across modern guidelines is individualization: the decision rests on a person's symptoms, their age and time since menopause, their personal and family medical history, and their own priorities. Where MHT is used, guidelines generally favor using an effective approach for as long as the benefits continue to outweigh the risks, with periodic review rather than a fixed, one-size-fits-all stopping point.

This is educational background, not a recommendation to start, continue, or stop any treatment. For related background see our treatments, conditions, and hormones sections, our blood tests section, and other evidence overviews in the studies index, including hormones and bone health.